Skip to content

Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes

Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01978405
Enrollment
200
Registered
2013-11-07
Start date
2013-11-30
Completion date
2014-06-30
Last updated
2013-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, The Changes of Endothelium-dependent Arterial Dilation, The Changes of Plasma Creatinine, The Changes of Plasma Free Radicals

Keywords

Type 2 diabetes, Nephropathy, Contrast medium, Alpha lipoic acid

Brief summary

Contrast-induced acute kidney injury (CIAKI) is a major complication with adverse outcomes after contrast media injection. Although the risk of developing CIAKI is low in patients with normal renal function, it is dramatically higher in patients with conditions such as diabetes mellitus (DM) or chronic kidney disease (CKD). More recently, our data showed that contrast agents can induce endothelial dysfunction partially via free radicals in diabetes. Therefore, strategies to prevent CIAKI and endothelial dysfunction in DM patients with CKD are urgently needed. Alpha-lipoic acid and its reduced form, dihydrolipoate, are potent antioxidants. We hypothesized that alpha lipoic acid can prevent the contrast-induced acute kidney injury and endothelial dysfunction in type 2 diabetes.

Interventions

DRUGAlpha lipoic acid

Sponsors

Xiang Guang-da
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* type 2 diabetes * nephropathy (stage 3 and 4)

Exclusion criteria

* recive alpha lipoic acid * type 1 diabetes * nephropathy (stagte 1, 2 and 5) * hypersensitivity to contrast media * IV heart failure * lactic acidosis

Design outcomes

Primary

MeasureTime frame
Contrast induced acte kidney injury6 months
The changes of endothelium-dependent arterial dilation before and after contrast administrated6 months

Countries

China

Contacts

Primary ContactXiang Guangda, MD
Guangda64@hotmail.com+8602768878410

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026